VIVS logo

VivoSim Labs Inc

VIVS

Build a strategy around VIVS

Accountable AI Logo

VivoSim Labs Inc AI Insights

Informational only. Not investment advice.
As of 2026-01-28

Snapshot

  • TTM revenue of 140K with 98.6% gross margin but -12.2M operating loss - classic pre-commercial biotech burning cash on R&D (4.6M TTM)[Operating Income TTM]
  • 10M unusual items TTM (likely one-time gain) masks underlying -12M operating loss; cash dropped 26% from 9.2M to 6.8M[Total Unusual Items TTM]
  • Cash runway ~6-8 months at current burn rate (-2.4M quarterly); 700K debt with 6.7M cash provides minimal buffer[Cash and Equivalents]

Watch Triggers

  • Cash and Equivalents: Falls below 4M or financing announcedSub-4M triggers going concern risk; terms of any raise reveal market confidence
  • Total Revenue TTM: Exceeds 1M quarterlyWould signal commercial traction or licensing deal - thesis-changing event
  • Research and Development TTM: Drops >30% without revenue increaseCould indicate pipeline abandonment or pivot away from core programs

Bull Case

98.6% gross margin (138K/140K TTM) indicates high-value IP/licensing model; if pipeline succeeds, operating leverage is massive

Gross Profit TTMCost of Revenue TTM

R&D of 4.6M TTM (33x revenue) signals active pipeline development; single approval could transform valuation

Research and Development TTM

Bear Case

Cash runway under 12 months with no recent financing; dilution or distressed deal highly probable

Cash and EquivalentsOperating Income TTM

140K TTM revenue is essentially zero commercial traction; 638K asset impairment suggests pipeline setbacks

Total Revenue TTMAsset Impairment Charge TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
25%

Leverage VIVS's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Dilutive financing likely within 6-12 months given burn rate and minimal revenue

3-12mhigh
  • 6.7M cash vs 12.2M annual operating loss
  • Zero capital issuance TTM suggests equity raise imminent
  • R&D spend of 4.6M indicates ongoing trials requiring funding
Cash declined 26% YoY (9.2M to 6.8M)Operating loss -12.2M TTMIssuance of capital stock: $0 TTM

Valuation Context

Caveats

Public Strategies Rankings

See how VivoSim Labs Inc ranks across different investment strategies.

Leverage VIVS's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.